DOCSLIB.ORG

Glucose-Induced Changes in Gene Expression in Human Pancreatic Islets: Causes Or Consequences of Chronic Hyperglycemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glucose-Induced Changes in Gene Expression in Human Pancreatic Islets: Causes Or Consequences of Chronic Hyperglycemia Diabetes Volume 66, December 2017 3013 Glucose-Induced Changes in Gene Expression in Human Pancreatic Islets: Causes or Consequences of Chronic Hyperglycemia Emilia Ottosson-Laakso,1 Ulrika Krus,1 Petter Storm,1 Rashmi B. Prasad,1 Nikolay Oskolkov,1 Emma Ahlqvist,1 João Fadista,2 Ola Hansson,1 Leif Groop,1,3 and Petter Vikman1 Diabetes 2017;66:3013–3028 | https://doi.org/10.2337/db17-0311 Dysregulation of gene expression in islets from patients In patients with type 2 diabetes (T2D), islet function de- with type 2 diabetes (T2D) might be causally involved clines progressively. Although the initial pathogenic trigger in the development of hyperglycemia, or it could develop of impaired b-cell function is still unknown, elevated glu- as a consequence of hyperglycemia (i.e., glucotoxicity). cose levels are known to further aggravate b-cell function, a To separate the genes that could be causally involved condition referred to as glucotoxicity, which can stimulate in pathogenesis from those likely to be secondary to hy- apoptosis and lead to reduced b-cell mass (1–5). Prolonged perglycemia, we exposed islets from human donors to exposure to hyperglycemia also can induce endoplasmic re- ISLET STUDIES normal or high glucose concentrations for 24 h and ana- ticulum (ER) stress and production of reactive oxygen spe- fi lyzed gene expression. We compared these ndings with cies (6), which can further impair islet function and thereby gene expression in islets from donors with normal glucose the ability of islets to secrete the insulin needed to meet the tolerance and hyperglycemia (including T2D). The genes increased demands imposed by insulin resistance and obe- whose expression changed in the same direction after sity (7). Although these changes are likely to contribute to short-term glucose exposure, as in T2D, were considered most likely to be a consequence of hyperglycemia. Genes deterioration of islet function in patients with manifest whose expression changed in hyperglycemia but not disease, they are less likely to explain the development of after short-term glucose exposure, particularly those T2D in individuals with normoglycemia. In previous studies, we analyzed the gene expression that also correlated with insulin secretion, were consid- fi ered the strongest candidates for causal involvement pro le in individuals with chronically elevated glucose as in T2D. For example, ERO1LB, DOCK10, IGSF11,and measured by elevated HbA1c levels (8,9). However, these PRR14L were downregulated in donors with hyperglyce- studies could not demonstrate whether the changes in gene mia and correlated positively with insulin secretion, expression are the cause or the consequence of hyperglyce- suggesting a protective role, whereas TMEM132C was mia.Onewaytoaddressthisquestionistocomparegene upregulated in hyperglycemia and correlated negatively expression in islets chronically exposed to hyperglycemia with insulin secretion, suggesting a potential pathogenic (prediabetes or diabetes) with gene expression changes after role. This study provides a catalog of gene expression short-term exposure to hyperglycemia, with the assump- changes in human pancreatic islets after exposure to tion that gene expression changes seen in islets from pa- glucose. tients with T2D but not after short-term hyperglycemia are the cause rather than the consequence of hyperglycemia (i.e., contributing to the pathogenesis of T2D). Thus, we The function of pancreatic islets is critical for maintaining performed RNA sequencing of human islets incubated at glucose homeostasis, and dynamic changes of gene expres- physiological (5.5 mmol/L) and high (18.9 mmol/L) glucose sion is part of the islets’ response to blood glucose changes. concentrations and compared the glucose-regulated genes 1Lund University Diabetes Centre, Department of Clinical Sciences, Lund Univer- This article contains Supplementary Data online at http://diabetes sity, Malmö, Sweden .diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0311/-/DC1. 2 Department of Epidemiology Research, Statens Serum Institut, Copenhagen, © 2017 by the American Diabetes Association. Readers may use this article as Denmark long as the work is properly cited, the use is educational and not for profit, and the 3 Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland work is not altered. More information is available at http://www.diabetesjournals Corresponding author: Emilia Ottosson-Laakso, emilia.ottosson@scilifelab.se. .org/content/license. Received 12 March 2017 and accepted 30 August 2017. 3014 Glucose-Induced Changes in Gene Expression Diabetes Volume 66, December 2017 with the gene expression profile seen in islets from hyper- annotation to guide the alignment, and featureCounts (15) glycemic donors (8). was used to count the number of reads aligned to the genes. Samples with ,10 million counts and genes with ,2counts RESEARCH DESIGN AND METHODS per million (CPM) in $10 samples were excluded from Donors and Islet Culture further analysis. The raw counts were transformed to log2 Human islets of Langerhans were obtained from the CPM, and the mean-variance trend was identified by using Human Tissue Laboratory (Lund University), which is funded mean-variance modeling at the observational level (voom) (16) by the Excellence Of Diabetes Research in Sweden (EXODIAB) to allow for linear modeling after batch correction with network (www.exodiab.se/home) in collaboration with The ComBat (17). Differential expression was analyzed by using Nordic Network for Clinical Islet Transplantation Program the paired data for 31 pairs of normoglycemic donor islets # (www.nordicislets.org). All islet donors had given consent (HbA1c 6% [42 mmol/mol]) and 14 pairs of hyperglycemic for donation of organs for medical research, and the proce- donor islets (HbA1c .6% [42 mmol/mol]) separately by dures were approved by the ethics committee at Lund Univer- fitting a linear model with linear models for microarray sity (Malmö, Sweden; permit number 2011263). The islets and RNA sequencing data (limma) (18). To exclude that were prepared from cadaver donors by using enzymatic diges- the number of genes responding to glucose was not due to tion and density gradient separation. Islet preparation purity differences in group size, we permuted 14 normoglycemic and count were determined as described previously (10). Be- samples 1,000 times and calculated the mean number of tween 3,000 and 5,000 islets each from 45 donors were di- changed genes by using the R function sample (19). vided into two pools that were incubated for 24 h in CMRL Linear modeling also was used to analyze differential gene ex- 1066 medium (ICN Biomedicals) containing 5.5 mmol/L or pression (adjusted for age, sex, and days in culture) in untreated 18.9 mmol/L glucose at 37°C. The study design is described islets from 81 donors with normoglycemia (HbA1c ,6% [42 A in Fig. 1 , and the clinical characteristics of the donors can mmol/mol]), 19 donors with hyperglycemia (HbA1c ,6.5% be found in Supplementary Table 1. RNA from the islets [48 mmol/mol]), and 16 donors with T2D (HbA1c $6.5% was extracted by using the miRNeasy Mini Kit (QIAGEN). [48 mmol/mol]), including the samples in the glucose-treated RNA quantity and integrity was assessed with an ND-1000 data set and overlapping a previous study by us (8). The HbA1c spectrophotometer (NanoDrop) and on a 2100 Bioanalyzer cutoffs for the groups were chosen to reflect the increased – or a 2200 TapeStation instrument (Agilent Technologies). risk seen in individuals with HbA1c 6.0 6.5% and to follow the recommendations by the International Expert Commit- Sample Preparation and Sequencing tee Report on the Role of the A1C Assay in the Diagnosis With RNA sequencing, we performed a truly global analysis of Diabetes (20). without a priori assumptions (11). A total of 1-mg high-quality RNA (RNA integrity number $8)wasusedasinputforthe The Effect of Coding Variants on In Vivo Insulin Secretion TruSeq RNA Library Preparation Kit (Illumina). The resulting To test the effect of gene expression on insulin secretion libraries were quality controlled on a 2200 TapeStation in vivo in humans, we used exome genotype array data to instrument before sequencing on a HiSeq 2000 system (Illu- find potential loss-of-function and gain-of-function variants mina) for an average depth of 32.4 mol/L paired-end reads in filtered genes. Genotypes with a frequency .5% from (2 3 100 base pairs). the human Infinium Exome-24 v1.1 array (Illumina) Insulin Secretion were obtained from the Prevalence, Prediction and Preven- Insulin secretion capacity of the islet preparations was tion-Botnia study (21), and association with corrected insulin evaluated by stimulatory index (SI). Twenty handpicked response (CIR) was performed, adjusted for age, sex, and P , islets were perifused with low glucose (1.67 mmol/L) for BMI, in 3,720 samples; unadjusted 0.05 was considered fi 42 min, high glucose (20 mmol/L) for 48 min, and then low nominally signi cant. The single nucleotide polymorphisms glucose again. Fractions were collected at 6-min intervals, and (SNPs) in coding parts of the gene were considered as po- the secreted insulin was measured by ELISA. SI was defined tential loss-of-function/gain-of-function variants. as the ratio between the areas under the curve calculated for Expression Quantitative Trait Loci Analysis in the Human the low and high glucose concentrations (12). SI was used for Islets all estimates of insulin secretion in the in vitro experiments. Islet expression
Load more

Recommended publications
  • A Mendelian Randomization Study Zhifa Han1†, Rui Tian1†, Peng Ren1, Wenyang Zhou1, Pingping Wang1, Meng Luo1, Shuilin Jin2* and Qinghua Jiang1*
    Han et al. BMC Medical Genetics 2018, 19(Suppl 1):0 https://doi.org/10.1186/s12881-018-0721-7 RESEARCH Open Access Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study Zhifa Han1†, Rui Tian1†, Peng Ren1, Wenyang Zhou1, Pingping Wang1, Meng Luo1, Shuilin Jin2* and Qinghua Jiang1* From 29th International Conference on Genome Informatics Yunnan, China. 3-5 December 2018 Abstract Background: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the top two common neurodegenerative diseases in elderly. Recent studies found the α-synuclein have a key role in AD. Although many clinical and pathological features between AD and PD are shared, the genetic association between them remains unclear, especially whether α-synuclein in PD genetically alters AD risk. Results: We did not obtain any significant result (OR = 0.918, 95% CI: 0.782–1.076, P = 0.291) in MR analysis between PD and AD risk. In MR between α-synuclein in PD with AD risk, we only extracted rs356182 as the IV through a strict screening process. The result indicated a significant association based on IVW method (OR = 0. 638, 95% CI: 0.485–0.838, P = 1.20E-03). In order to examine the robustness of the IVW method, we used other three complementary analytical methods and also obtained consistent results. Conclusion: The overall PD genetic risk factors did not predict AD risk, but the α-synuclein susceptibility genetic variants in PD reduce the AD risk. We believe that our findings may help to understand the association between them, which may be useful for future genetic studies for both diseases.
    [Show full text]
  • Dual Proteome-Scale Networks Reveal Cell-Specific Remodeling of the Human Interactome
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Dual Proteome-scale Networks Reveal Cell-specific Remodeling of the Human Interactome Edward L. Huttlin1*, Raphael J. Bruckner1,3, Jose Navarrete-Perea1, Joe R. Cannon1,4, Kurt Baltier1,5, Fana Gebreab1, Melanie P. Gygi1, Alexandra Thornock1, Gabriela Zarraga1,6, Stanley Tam1,7, John Szpyt1, Alexandra Panov1, Hannah Parzen1,8, Sipei Fu1, Arvene Golbazi1, Eila Maenpaa1, Keegan Stricker1, Sanjukta Guha Thakurta1, Ramin Rad1, Joshua Pan2, David P. Nusinow1, Joao A. Paulo1, Devin K. Schweppe1, Laura Pontano Vaites1, J. Wade Harper1*, Steven P. Gygi1*# 1Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA. 2Broad Institute, Cambridge, MA, 02142, USA. 3Present address: ICCB-Longwood Screening Facility, Harvard Medical School, Boston, MA, 02115, USA. 4Present address: Merck, West Point, PA, 19486, USA. 5Present address: IQ Proteomics, Cambridge, MA, 02139, USA. 6Present address: Vor Biopharma, Cambridge, MA, 02142, USA. 7Present address: Rubius Therapeutics, Cambridge, MA, 02139, USA. 8Present address: RPS North America, South Kingstown, RI, 02879, USA. *Correspondence: edward_huttlin@hms.harvard.edu (E.L.H.), wade_harper@hms.harvard.edu (J.W.H.), steven_gygi@hms.harvard.edu (S.P.G.) #Lead Contact: steven_gygi@hms.harvard.edu bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD (cevansmo@iu.edu) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence After Radical Prostatectomy
    Int. J. Mol. Sci. 2015, 16, 3856-3869; doi:10.3390/ijms16023856 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy Chinyere Ibeawuchi 1, Hartmut Schmidt 2, Reinhard Voss 3, Ulf Titze 4, Mahmoud Abbas 5, Joerg Neumann 6, Elke Eltze 7, Agnes Marije Hoogland 8, Guido Jenster 9, Burkhard Brandt 10 and Axel Semjonow 1,* 1 Prostate Center, Department of Urology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebaeude 1A, Muenster D-48149, Germany; E-Mail: prostata@uni-muenster.de 2 Center for Laboratory Medicine, University Hospital Muenster, Albert-Schweitzer-Campus 1, Gebaeude 1A, Muenster D-48149, Germany; E-Mail: Hartmut.Schmidt-ZL@ukmuenster.de 3 Interdisciplinary Center for Clinical Research, University of Muenster, Albert-Schweitzer-Campus 1, Gebaeude D3, Domagkstrasse 3, Muenster D-48149, Germany; E-Mail: voss@uni-muenster.de 4 Pathology, Lippe Hospital Detmold, Röntgenstrasse 18, Detmold D-32756, Germany; E-Mail: u.titze@web.de 5 Institute of Pathology, Mathias-Spital-Rheine, Frankenburg Street 31, Rheine D-48431, Germany; E-Mail: mahmoud.abbas@pathomail.de 6 Institute of Pathology, Klinikum Osnabrueck, Am Finkenhuegel 1, Osnabrueck D-49076, Germany; E-Mail: joerg.neumann@pathomail.de 7 Institute of Pathology, Saarbrücken-Rastpfuhl, Rheinstrasse 2, Saarbrücken D-66113, Germany; E-Mail: e.eltze@pathologie-saarbruecken.de 8 Department
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]
  • NIH Public Access Author Manuscript Hum Genet
    NIH Public Access Author Manuscript Hum Genet. Author manuscript; available in PMC 2015 May 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Hum Genet. 2014 May ; 133(5): 509–521. doi:10.1007/s00439-013-1387-z. A genome-wide association study of prostate cancer in West African men Michael B. Cook1,*, Zhaoming Wang1,2,*, Edward D. Yeboah3,4,*, Yao Tettey3,4, Richard B. Biritwum3,4, Andrew A. Adjei3,4, Evelyn Tay3,4, Ann Truelove5, Shelley Niwa5, Charles C. Chung1, Annand P. Chokkalingam6, Lisa W. Chu7, Meredith Yeager1,2, Amy Hutchinson1,2, Kai Yu1, Kristin A. Rand8, Christopher A. Haiman8, African Ancestry Prostate Cancer GWAS Consortium, Robert N. Hoover1, Ann W. Hsing6,9,#, and Stephen J. Chanock1,# 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA 2Cancer Genomics Research Laboratory, NCI-DCEG, SAIC-Frederick Inc., Frederick, MD, USA 3Korle Bu Teaching Hospital, PO BOX 77, Accra, Ghana 4University of Ghana Medical School, PO Box 4236, Accra, Ghana 5Westat, 1600 Research Boulevard, Rockville, MD 20850-3129, USA 6School of Public Health, University of California, Berkeley, CA, USA 7Cancer Prevention Institute of California, 2201 Walnut Avenue, Suite 300, Fremont, CA 94538, USA 8Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California. Los Angeles, CA 90033, USA 9Stanford Cancer Institute, Stanford University, 875 Blake Wilbur Drive Stanford, CA 94305 Abstract Background—Age-adjusted mortality rates for prostate cancer are higher for African American men compared with those of European ancestry. Recent data suggest that West African men also have elevated risk for prostate cancer relative to European men.
    [Show full text]
  • Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic Mirna Clusters
    Published OnlineFirst March 27, 2012; DOI: 10.1158/1078-0432.CCR-11-1078 Clinical Cancer Human Cancer Biology Research Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters Naohiro Nishida1,4, Makoto Nagahara2, Tetsuya Sato3, Koshi Mimori1, Tomoya Sudo1, Fumiaki Tanaka1, Kohei Shibata1, Hideshi Ishii1,4, Kenichi Sugihara2, Yuichiro Doki4, and Masaki Mori1,4 Abstract Purpose: Cancer stroma plays an important role in the progression of cancer. Although alterations in miRNA expression have been explored in various kinds of cancers, the expression of miRNAs in cancer stroma has not been explored in detail. Experimental Design: Using a laser microdissection technique, we collected RNA samples specific for epithelium or stroma from 13 colorectal cancer tissues and four normal tissues, and miRNA microarray and gene expression microarray were carried out. The expression status of miRNAs was confirmed by reverse transcriptase PCR. Furthermore, we investigated whether miRNA expression status in stromal tissue could influence the clinicopathologic factors. Results: Oncogenic miRNAs, including two miRNA clusters, miR-17-92a and miR-106b-25 cluster, were upregulated in cancer stromal tissues compared with normal stroma. Gene expression profiles from cDNA microarray analyses of the same stromal tissue samples revealed that putative targets of these miRNA clusters, predicted by Target Scan, such as TGFBR2, SMAD2, and BMP family genes, were significantly downregulated in cancer stromal tissue. Downregulated putative targets were also found to be involved in cytokine interaction and cellular adhesion. Importantly, expression of miR-25 and miR-92a in stromal tissues was associated with a variety of clinicopathologic factors. Conclusions: Oncogenic miRNAs were highly expressed in cancer stroma.
    [Show full text]
  • C-MYC Inhibition Impairs Hypoxia Response in Glioblastoma Multiforme
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 22 c-MYC inhibition impairs hypoxia response in glioblastoma multiforme Maria Patrizia Mongiardi1,*, Mauro Savino2,*, Maria Laura Falchetti1, Barbara Illi2, Francesca Bozzo3,4, Cristiana Valle1,4, Manuela Helmer-Citterich5, Fabrizio Ferrè6, Sergio Nasi2,**, Andrea Levi1,** 1Institute of Cell Biology and Neurobiology, CNR, c/o CERC, 00143 Rome, Italy 2 Nucleic Acids Laboratory, Institute of Molecular Biology and Pathology, National Research Council (IBPM-CNR) and Department of Biology and Biotechnologies, Sapienza University, 00185 Rome, Italy 3Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy 4Fondazione Santa Lucia IRCCS, c/o CERC, 00143 Rome, Italy 5 Centre for Molecular Bioinformatics, Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy 6 Department of Pharmacy and Biotechnology (FaBiT), University of Bologna Alma Mater, 40126 Bologna, Italy *These two authors contributed equally to this work **co-senior authors Correspondence to: Maria Patrizia Mongiardi, e-mail: mariapatrizia.mongiardi@ibcn.cnr.it Andrea Levi, e-mail: andrea.levi@cnr.it Keywords: HIF, c-MYC, hypoxia, glycolysis, glioblastoma Received: January 7, 2016 Accepted: March 31, 2016 Published: April 22, 2016 ABSTRACT The c-MYC oncoprotein is a DNA binding transcription factor that enhances the expression of many active genes. c-MYC transcriptional signatures vary according to the transcriptional program defined in each cell type during differentiation. Little is known on the involvement of c-MYC in regulation of gene expression programs that are induced by extracellular cues such as a changing microenvironment. Here we demonstrate that inhibition of c-MYC in glioblastoma multiforme cells blunts hypoxia- dependent glycolytic reprogramming and mitochondria fragmentation in hypoxia.
    [Show full text]
  • Molecular and Epigenetic Features of Melanomas and Tumor Immune
    Seremet et al. J Transl Med (2016) 14:232 DOI 10.1186/s12967-016-0990-x Journal of Translational Medicine RESEARCH Open Access Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab‑based immunotherapy in metastatic patients Teofila Seremet1,3*† , Alexander Koch2†, Yanina Jansen1, Max Schreuer1, Sofie Wilgenhof1, Véronique Del Marmol3, Danielle Liènard3, Kris Thielemans4, Kelly Schats5, Mark Kockx5, Wim Van Criekinge2, Pierre G. Coulie6, Tim De Meyer2, Nicolas van Baren6,7 and Bart Neyns1 Abstract Background: Ipilimumab (Ipi) improves the survival of advanced melanoma patients with an incremental long-term benefit in 10–15 % of patients. A tumor signature that correlates with this survival benefit could help optimizing indi- vidualized treatment strategies. Methods: Freshly frozen melanoma metastases were collected from patients treated with either Ipi alone (n: 7) or Ipi combined with a dendritic cell vaccine (TriMixDC-MEL) (n: 11). Samples were profiled by immunohistochemistry (IHC), whole transcriptome (RNA-seq) and methyl-DNA sequencing (MBD-seq). Results: Patients were divided in two groups according to clinical evolution: durable benefit (DB; 5 patients) and no clinical benefit (NB; 13 patients). 20 metastases were profiled by IHC and 12 were profiled by RNA- and MBD-seq. 325 genes were identified as differentially expressed between DB and NB. Many of these genes reflected a humoral and cellular immune response. MBD-seq revealed differences between DB and NB patients in the methylation of genes linked to nervous system development and neuron differentiation. DB tumors were more infiltrated by CD8+ and PD-L1+ cells than NB tumors.
    [Show full text]
  • Multipoint Association Mapping for Longitudinal Family Data: an Application to Hypertension Phenotypes Yen-Feng Chiu1*, Chun-Yi Lee1 and Fang-Chi Hsu2
    The Author(s) BMC Proceedings 2016, 10(Suppl 7):54 DOI 10.1186/s12919-016-0049-2 BMC Proceedings PROCEEDINGS Open Access Multipoint association mapping for longitudinal family data: an application to hypertension phenotypes Yen-Feng Chiu1*, Chun-Yi Lee1 and Fang-Chi Hsu2 From Genetic Analysis Workshop 19 Vienna, Austria. 24-26 August 2014 Abstract It is essential to develop adequate statistical methods to fully utilize information from longitudinal family studies. We extend our previous multipoint linkage disequilibrium approach—simultaneously accounting for correlations between markers and repeat measurements within subjects, and the correlations between subjects in families—to detect loci relevant to disease through gene-based analysis. Estimates of disease loci and their genetic effects along with their 95 % confidence intervals (or significance levels) are reported. Four different phenotypes—ever having hypertension at 4 visits, incidence of hypertension, hypertension status at baseline only, and hypertension status at 4 visits—are studied using the proposed approach. The efficiency of estimates of disease locus positions (inverse of standard error) improves when using the phenotypes from 4 visits rather than using baseline only. Background so estimating the position of a disease locus and its stand- Approaches for analyzing longitudinal family data have ard error is robust to a wide variety of genetic mecha- been categorized into 2 groups [1]: (a) first summarizing nisms; (b) it provides estimates of disease locus positions, repeated measurements into 1 statistic (eg, a mean or along with a confidence interval for further fine mapping; slope per subject) and then using the summarized statis- and (c) it uses linkage disequilibrium between markers to tic as a standard outcome for genetic analysis; or (b) localize the disease locus, which may not have been typed.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Identification of Key Genes and Pathways in Pancreatic Cancer
    G C A T T A C G G C A T genes Article Identification of Key Genes and Pathways in Pancreatic Cancer Gene Expression Profile by Integrative Analysis Wenzong Lu * , Ning Li and Fuyuan Liao Department of Biomedical Engineering, College of Electronic and Information Engineering, Xi’an Technological University, Xi’an 710021, China * Correspondence: luwenzong@xatu.edu.cn; Tel.: +86-29-86173358 Received: 6 July 2019; Accepted: 7 August 2019; Published: 13 August 2019 Abstract: Background: Pancreatic cancer is one of the malignant tumors that threaten human health. Methods: The gene expression profiles of GSE15471, GSE19650, GSE32676 and GSE71989 were downloaded from the gene expression omnibus database including pancreatic cancer and normal samples. The differentially expressed genes between the two types of samples were identified with the Limma package using R language. The gene ontology functional and pathway enrichment analyses of differentially-expressed genes were performed by the DAVID software followed by the construction of a protein–protein interaction network. Hub gene identification was performed by the plug-in cytoHubba in cytoscape software, and the reliability and survival analysis of hub genes was carried out in The Cancer Genome Atlas gene expression data. Results: The 138 differentially expressed genes were significantly enriched in biological processes including cell migration, cell adhesion and several pathways, mainly associated with extracellular matrix-receptor interaction and focal adhesion pathway in pancreatic cancer. The top hub genes, namely thrombospondin 1, DNA topoisomerase II alpha, syndecan 1, maternal embryonic leucine zipper kinase and proto-oncogene receptor tyrosine kinase Met were identified from the protein–protein interaction network.
    [Show full text]